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Abstract
We aim to develop an efﬁcient and non-invasive strategy for monitoring of drugs and their metabolites via human
skin. Probe sampling was combined with thermal desorption-electrospray ionization tandem mass spectrometry (TDESI/MS/MS) to characterize trace terbinaﬁne, which was secreted on patient's skin after ingesting terbinaﬁne tablets. The
terbinaﬁne ion signals were directly detected in the samples collected from different skin regions and the signals were
monitored for 8 weeks. The detection and location of terbinaﬁne via the skin suggest that the methods are useful in
rapidly and noninvasively collecting the molecular information of the ingested drug on skin for pharmacokinetic
studies.
Keywords: Epidermis, Skin, Terbinaﬁne, Thermal desorption-electrospray ionization tandem mass spectrometry

1. Introduction

S

kin is the largest human organ and plays a
crucial role in protecting the body against
numerous pathogens present in the external

environment. Many metabolites are also secreted
out onto skin through subcutaneous tissues like
sweat glands and sebaceous glands. Since the
secreted compounds on skin are mainly metabolic
products or byproducts from various biological
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systems (e.g. circulatory, immune, lymphatic, etc.),
changes in skin metabolite proﬁles can grant insight
into pathophysiological changes of the studied individuals [1]. For this reason, research on skin metabolites has been a topic of interest over the last
several decades [2e6]. Skin metabolites are therefore of clinical interest to the areas of medical
diagnosis, organ pathophysiology, forensics, toxicology, exposomics, and anti-doping [7e13].
Although sebum or sweat samples can be noninvasively collected from the surface of skin, trace
amounts of these secretions complicate sampling,
detection and analysis. Thus, a sensitive analytical
platform is needed to efﬁciently sample and detect
trace metabolites in sebum. The approaches for
efﬁciently collecting sebum include skin contact
sampling and headspace sampling [1]. For the skin
contact approach, sampling devices, strips and
patches are placed on skin for a certain period of
time to collect enough semi-volatile and non-volatile analytes. Liquid-absorbing materials are widely
used to make sampling devices and patches,
including semi-permeable sweat patches, isopropyl
alcohol swabs, cotton pads, textile material probes,
agarose hydrogel, and polydimethylsiloxane
(PDMS) devices [14,15]. A headspace approach used
a solid-phase microextraction (SPME) ﬁber for
concentrating volatiles and semi-volatile metabolites on skin [2,16e18]. Although skin metabolites
are successfully detected by the contact sampling
approaches, the analytical processes including
sampling, extraction, concentration and characterization are usually time and labor-consuming.
There have been substantial efforts to develop and
integrate in vivo and in situ skin sampling techniques
with state-of-the-art analytical instruments [2]. Gas
chromatography/mass spectrometry (GC/MS) is the
most widely used technique for characterizing
sebum analytes including volatile organic compounds (VOCs), metabolites, disease biomarkers,
aroma compounds, and lipid molecules [19e23].
Although GC/MS is highly regarded for its sensitive,
qualitative and quantitative capabilities for sebum
analysis, the analytical throughput is still low for its
requirement of extensive sample preparation processes. On the other hand, liquid chromatography/
mass spectrometry (LC-MS) and matrix-assisted
laser desorption ionization time-of-ﬂight mass
spectrometry (MALDI-TOF/MS) were used to characterize speciﬁc epidermal compounds and created
molecular topographical maps [24e28]. Cotton
swabs or skin tape strips were used to perform
sampling. However time-consuming and laborintensive sample treatment such as solvents extractions, concentration, chromatographic analysis, and

matrix deposition are still needed for both
approaches.
Alternatively, AIMS has been demonstrated to be
useful for rapidly characterizing samples from the
skin [18,29e33]. Ambient ionization mass spectrometry (AIMS) encompasses the features of
traditional mass spectrometric techniques but
operates under ambient conditions and require
minimal or no sample pretreatment, making AIMS
highly applicable for in situ and real-time sample
analysis [34e36]. In this study, we used thermal
desorption-electrospray ionization/mass spectrometry (TD-ESI/MS) to conduct a non-invasive drug
monitoring on human skin. TD-ESI/MS uses a
metallic probe to sweep sample surfaces to collect
analytes prior to their thermal desorption, electrospray ionization, and mass spectrometric detection.
Since analyte desorption and ionization are
restricted within a very small area, the ionization
efﬁciency of the technique is extremely high [37].
The detection limits of TD-ESI/MS for common
organic compounds are within sub-ppm levels in
full scan mode, and ppb levels in multiple reaction
monitoring (MRM) mode [37]. A TD-ESI/MS/MS
analysis is typically completed in less than 15 s,
enabling high-throughput screening of a large
number of samples [38e48]. Applications of TD-ESI/
MS/MS in biomedicine include the detection of (1)
semi-volatile chemical compounds such as ingested
pesticides and drugs in biological ﬂuids for emergency care [42e46], (2) active ingredients in pharmaceutical products [38], and (3) drugs in plasma for
pharmacokinetic studies [47,48]. In our previous
study, TD-ESI/MS has been used to rapidly characterize sebaceous lipids [34]. Compared to the
other AIMS approaches which were used to analyze
skin surface lipids [30e33], the lipid proﬁle of TDESI/MS is unique. All major classes of sebaceous
lipids, including the unsaturated hydrocarbons (SQ)
and nonpolar lipids (e.g. cholesterol), can be directly
and rapidly detected without any sample treatment
[34]. It is likely due the high temperature makes
charged electrospray droplets dry faster, gas-phase
ion/molecule reactions play a role in TD-ESI source
for the ionization of thermal desorbed analytes [33].
Since the sampling and analysis for TD-ESI/MS
and TD-ESI/MS/MS is non-invasive, sensitive,
rapid, and capable of polar/nonpolar compounds,
trace medicine secreted on skin can then be rapidly
collected and analyzed. Herein, the capability of TDESI/MS/MS to detect the anti-fungal agent - terbinaﬁne on skin of a patient who orally ingested terbinaﬁne tablets for 12 weeks was ﬁrst examined.
Terbinaﬁne is an allylamine-class agent that selectively inhibits the fungal squalene epoxidase and

has broad-spectrum activity against yeasts, fungi,
molds, and dermatophytes. Terbinaﬁne is clinically
used for oral or topical treatment of mycoses of the
skin such as onychomycosis, ringworm, and tinea
capitis, where treatment duration depends on
infection type and severity [49e53]. Terbinaﬁne is
highly lipophilic compound and tends to accumulate in sebum, hair, nail, and stratum corneum to
play its primarily fungicidal action. Generally,
pharmacokinetic studies of an oral drug could show
that each drug administered will achieve its therapeutic concentration in the blood. In the case of
terbinaﬁne, directly detecting the drug on the skin
surface can provide physicians more accurate and
rapid information of the target skin area for treatment. A modiﬁcation of the dosage of the drug can
then be made promptly if there are any clinical
concerns. In previous study, terbinaﬁne in sebum,
hair, etc. samples was determined by high-performance liquid chromatography methods. In this
study, probe sampling was combined with TD-ESI/
MS/MS to characterize trace terbinaﬁne on different
skin areas, which was secreted on patient's skin after
ingesting terbinaﬁne tablets. The distribution of
terbinaﬁne on the skin was visualized using a
commercially available molecular mapping software. In addition, terbinaﬁne ion signals on skin
samples were monitored for 8 weeks after the test
subject stopped taking the terbinaﬁne tablets.

2. Experimental
2.1. Reagents and standards
Methanol (HPLC-grade) and glacial acetic acid
(reagent-grade) were purchased from Merck
(Darmstadt, Germany) and J.T. Baker (Phillipsburg,
NJ, U.S.A.), respectively. Distilled deionized water
(puriﬁed with a PURELAB Classic UV from ELGA,
Marlow, U.K.) was used to prepare the electrospray
solution and standard solutions. All reagents and
solvents were used without further puriﬁcation.
Pure terbinaﬁne standard was purchased from
SigmaeAldrich (St. Louis, U.S.A.). Stock solution of
the terbinaﬁne was prepared in methanol at an
initial concentration of 10 mg/mL and then serially
diluted to 0.1 ng/mL prior to further analysis.
2.2. Instrumentation
The TD-ESI mass spectrometric system was set up
as described in our previous publication [37]. In brief,
TD-ESI/MS is comprised of direct sampling probes, a
thermal desorption unit, an electrospray ionization
unit, and a triple quadrupole mass analyzer (Ultivo,
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Agilent, Santa Clara, U.S.A.). The probe used to
collect samples was comprised of a stainless steel
inoculating loop (diameter 2 mm, length 60 mm;
Ching Ming Medical Device Co., Ltd. Taipei, Taiwan)
which was screw-fastened to a probe holder by a pin
clasp embedded in the holder. The temperature in
the TD-ESI source was set at 280  C d the optimized
desorption temperature for terbinaﬁne analysis d
using a temperature controller (ANLY AT-502, Taipei, Taiwan). A hot nitrogen stream ﬂowed at a
pressure of 3 L/min from the top of the TD unit to
deliver the thermally desorbed analytes into the ESI
plume. The ESI solution comprised of methanol/
water (1:1, v/v) with 0.1% acetic acid (v/v) was ﬂown
through a fused-silica capillary (inner diameter
100 mm) at a ﬂow rate of 120 mL/h. A high voltage
(þ5 kV) was applied to the ESI capillary to induce ESI
of the solution ﬂowing out of the capillary via solution conduction. No additional nebulizing gas was
used to assist with electrospray in this study. MS and
MS/MS analyses were performed in positive ion
mode to obtain mass spectra of molecular and precursor-product ions, respectively. MS analysis was
conducted in full scan mode, while MS/MS analysis
was performed in MRM mode using a normalized
collision energy of 15 V.
2.3. Sebum sampling and analysis
Sebum samples were collected from a 22-year-old
male volunteer who had diagnosed with onychomycosis and orally ingested terbinaﬁne tablets for
12 weeks and a 22-year-old male volunteer with
healthy skin, the latter of whom served as the
healthy control. Samples were obtained after ethical
review and approval by an institutional review
board (KMUHIRB-E(I)-20160174), with informed
consent given by both volunteers before
commencing the study. To treat his onychomycosis,
the onychomycosis patient was prescribed Lamisil®
Tablets (250 mg/day of terbinaﬁne hydrochloride).
Figure 1a shows the process of in situ sampling of
the skin surface using a sampling probe. The skin
was cleaned with an Alcohol Prep Pad (China Surgical Dressings Center Co. Ltd., Changhua, Taiwan)
prior to sampling. The sebum samples were
collected by gently sweeping the inoculating loop
for 2 cm across the skin. Liquid samples were
collected by dipping the inoculating loop into terbinaﬁne standard solutions to collect 2 mL of the
solution on the loop. After sampling, the probe was
inserted into the TD-ESI source for subsequent MS
analysis (Fig. 1b).
To explore the optimal mass spectrometric parameters and limit of detection (LOD) for
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Fig. 1. Workﬂow of sebum analysis using TD-ESI/MS/MS, which involves (a) sampling by sweeping the sampling probe for 2 cm across the skin
surface (e.g. the forehead) after cleaning with Alcohol Prep Pad 1 h, (b) inserting the probe into the TD-ESI unit, (c) obtaining the MS and MS/MS
mass spectra, and (d) cleaning the probe with a ﬂame.

terbinaﬁne, liquid standards were analyzed using
TD-ESI/MS (full scan mode) and TD-ESI/MS/MS
(MRM mode), respectively (Fig. 1c). A terbinaﬁne
calibration curve was constructed by analyzing
standards with concentrations ranging from 0.5 to
100 ng/mL in MeOH. The capability of TD-ESI/MS
for characterizing terbinaﬁne that is directly applied
on skin was also explored. The skin of the hand was
ﬁrst cleaned with an alcohol prep pad. Immediately,
a terbinaﬁne standard solution (2 mL, 100 ng/mL)
was spread evenly over an area of 2 cm  2 cm on
the back of the hand of the healthy control (for
whom no baseline terbinaﬁne ion signals were
detected) and allowed to air-dry. Sampling was then
performed by gently sweeping the probe for 2 cm
across the terbinaﬁne-smeared region of skin. Ten
consecutive analyses of the samples collected from
this region were performed, and the relative standard deviation (RSD) of the ten analysis was
calculated.
To analyze the levels of secreted terbinaﬁne with
TD-ESI/MS/MS, sebum samples were collected
after the onychomycosis patient had ingested Lamisil® Tablets daily for 2 weeks to allow internal terbinaﬁne concentrations to reach homeostasis. Skin
sampling was performed by gently sweeping the

probe for 2 cm across the patient's alcohol-cleaned
forehead, after which the probe was inserted into
the TD-ESI source for analysis. TD-ESI/MS analysis
was used to analyze the degree of accumulation of
terbinaﬁne secreted on the skin by collecting sebum
samples before and after thoroughly washing the
skin, as well as to explore the decrease in terbinaﬁne
secreted onto the skin. After taking a terbinaﬁne
tablet (250 mg) daily for 12 weeks, the onychomycosis patient stopped the medication, and sebum
samples were collected and analyzed each week for
8 weeks overall.
After sample analysis, the probe loop was cleaned
by burning it for 3e4 s with a high-temperature
ﬂame from a handheld butane torch to remove any
residual organic compounds (Fig. 1d). Analysis of a
sample d including sampling, thermal desorption,
electrospray ionization, detection, and probe cleaning d was typically completed in approximately
30 s.
Various skin regions on both the onychomycosis
patient (who self-ingested terbinaﬁne for 2 weeks)
and the healthy control were sampled and analyzed.
Sebum samples were collected using multiple
probes, where the inoculating loop from each probe
was removed from the probe holder and inserted on
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Fig. 2. TIC and EIC of terbinaﬁne (m/z 292) for four consecutive analyses of sebum samples from (a) the healthy control who did not ingest terbinaﬁne, and (b) the onychomycosis patient who ingested terbinaﬁne for 2 weeks. (c) Peak areas of terbinaﬁne (MRM for m/z 292/141) of sebum
samples collected from the face of the onychomycosis patient before (Time ¼ 0) and after washing the skin.

a Styrofoam plate covered with a cardboard box,
with each plate holding up to 66 probes [36]. In this
study, 168 probes were used to collect samples from

28 locations on the body (i.e. triplicate analysis for
each sample location for two volunteers). Both the
patient and healthy control were sampled after
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Fig. 3. (a) Sketch map of 28 sampling locations of the onychomycosis patient: 1) forehead, 2) eyelid, 3) nose bridge, 4) cheek, 5) lips 6) chin, 7) ear
[inside], 8) earlobe, 9) ear [back], 10) neck, 11) chest, 12) upper arm, 13) cubital fossa, 14) armpit, 15) forearm, 16) hand [back], 17) palm, 18)
ﬁngertip, 19) ﬁngernail, 20) abdomen, 21) upper back, 22) lower back, 23) waist, 24) thigh, 25) popliteal fossa, 26) calf, 27) instep, and 28) sole; (b)
TIC of terbinaﬁne (MRM for m/z 292/141) for sebum samples from different body regions of the terbinaﬁne-medicated patient and the unmedicated
control. Numbers above each current indicate the sampled skin regions as designated by Fig. 3a; (c) whole-body molecular mapping of terbinaﬁne
detected on the skin of front, face, and back side.

taking a bath and waiting 1 h for sebum secretion,
where the entire sampling process was completed
within 30 min. TD-ESI/MS/MS analysis of the
sebum samples collected on each probe was conducted immediately after samples were collected
and transferred to the MS laboratory.

3. Results and discussion
The LOD for the detection of terbinaﬁne with TDESI/MS and TD-ESI/MS/MS was examined by
analyzing standard solutions at different concentrations. Two microliters of the sample solution was
deposited on the sampling probe with a micropipette. The probe was then inserted into the TD-ESI
source for analysis. Figure S1a shows the TD-ESI
mass spectra of terbinaﬁne (m/z 292, MHþ) recorded
from the aforementioned standard solutions with
terbinaﬁne concentrations of 0.1, 0.5, and 5 mg/mL in
MeOH, respectively. No terbinaﬁne ion signal (S/
N<3) was detected for the standard solution of
0.1 mg/mL, but was detected from the solutions
containing 0.5 and 5 mg/mL terbinaﬁne standards.
The LOD of terbinaﬁne was then estimated to be
between 0.1 and 0.5 mg/mL by using TD-ESI/MS
(full scan mode). Figure S1b shows the total ion
current (TIC) of terbinaﬁne detected from the solutions containing 1, 10, and 100 ng/mL terbinaﬁne
standards with TD-ESI/MS/MS. An ion transition of
m/z 292/141 for protonated terbinaﬁne ion and its
product ion was monitored during TD-ESI/MS/MS
analysis. The results indicated that the LOD of terbinaﬁne for TD-ESI/MS/MS was between 1 ng/mL
and 10 ng/mL, and that the detection sensitivity of
terbinaﬁne ions with TD-ESI/MS/MS operated in
MRM mode is at least 10 times better than that of
TD-ESI/MS operated in full scan mode. Figure S1c
shows the calibration curve for terbinaﬁne with TDESI/MS/MS, where a good linearity for quantifying
terbinaﬁne with concentrations between 1 and
100 ng/mL (R2 ¼ 0.9913) was obtained.
To simulate skin sampling, the solution (2 mL)
containing terbinaﬁne standard (100 ng/mL) was
applied on the back of the healthy control's palm
and smeared for ca. 2 cm  2 cm. After the solution
was allowed to air-dry, a metallic probe was gently
swept along the skin for 2 cm to collect a sample for
TD-ESI/MS/MS analysis. Figure S2 shows the

terbinaﬁne ion signal (MRM mode for the transition
of m/z 292/141) recorded from ten consecutive
analyses of the samples collected from the terbinaﬁne-smeared region. The relative standard deviation (RSD) of the ten analysis was calculated to be
16.38%, indicating that probe sampling combined
with TD-ESI/MS/MS analysis shows a reasonably
good repeatability for sebum sample analysis.
Figure 2 presents TIC and extracted an ion current
(EIC) of terbinaﬁne ion (m/z 292, MHþ, full scan
mode) from quadruplicate analyses of sebum samples collected from the forehead skin of the healthy
control (Fig. 2a) and terbinaﬁne-medicated patients,
respectively (Fig. 2b). Results of the analyses
showed that terbinaﬁne was not detected on the
forehead skin of the healthy control but was detected on that of the terbinaﬁne-medicated patient (EIC
mode). The results indicate that TD-ESI/MS full
scan mode is sensitive enough to detect trace terbinaﬁne ingested by the onychomycosis patient.
Assuming that 50% of the ingested terbinaﬁne
(250 mg) is secreted out of body through the skin (ca.
2 m2), there is approximately 6.25 mg/cm2 of terbinaﬁne on the skin. Assuming 10% of the skin terbinaﬁne on 1 cm2 is collected by probe sampling,
this means that 625 ng of terbinaﬁne is collected on
the probe during each sampling, which is far above
the LOD of TD-ESI/MS and TD-ESI/MS/MS
(Fig. S1). Figure 2c shows the peak area of terbinaﬁne ion signals (MRM for m/z 292/141) detected in
the sebum samples, which were collected before
(Time ¼ 0) and after washing the onychomycosis
patient's face with facial cleanser ﬁrst. As can be
seen, terbinaﬁne on the skin was dramatically
removed by the facial cleanser (Time ¼ wash), but
its ion signal increased again and reached nearly the
same level as it was in its pre-washed state 60 min
later. Therefore, pre-washed state 60 min was
served as the subsequent sebum sampling through
this study.
To study the distribution of terbinaﬁne on skin all
over the body, a total of 28 skin regions of the body
(10 on the face, 8 on the front body, 8 on the back
body, and 2 on the ﬁnger) were selected for triplicate sampling (Fig. 3a). A total of 168 samples was
collected for further TD-ESI/MS/MS analysis from
two volunteers. We think sebaceous compounds are
symmetrically distributed in right and left body, we
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choose one side of different regions to perform
sampling and analysis. Figure 3b shows the terbinaﬁne ion signal (MRM mode for the transition of
m/z 292/141) from the sebum samples collected
from different skin regions of the terbinaﬁnemedicated patient and the unmedicated healthy
control, respectively. The numbers (#1e28) represent where the samples were collected (Fig. 3a and
b). Terbinaﬁne ion signals were detected in most of
the sebum samples collected from the terbinaﬁnemedicated patient; in contrast, no terbinaﬁne ion
signals were detected in sebum samples collected
from the healthy control (Fig. 3b). In addition, terbinaﬁne ion signals varied among the samples
collected from different skin regions of the terbinaﬁne-medicated patient, indicating regional variations in terbinaﬁne secretion.
As is generally known, metabolites inside the
body are secreted from the body through either
sebaceous or sweat glands in the dermis. The
possible mechanisms of metabolite secretion
include the metabolites which circulate in the blood
vessels, reach the capillaries, and diffuse into the
dermis; they subsequently enter the glands and
secrete from the skin. Sweat glands secrete mostly
water and polar metabolites, while sebaceous
glands secrete primarily less polar or non-polar
metabolites [54]. Since terbinaﬁne is a non-polar
drug, it will be secreted to the skin mostly through
sebaceous glands. Indeed, sebaceous glands are
distributed all over the human body except for the
palms of the hands and soles of the feet, which explains why lower terbinaﬁne ion signals were
detected in samples collected from those skin regions (#16-19 in Fig. 3b). On the other hand, the face
and scalp have the highest density of sebaceous
glands (400-900 glands/cm2), as well as pilosebaceous units and meibomian glands (on the eyelids),
and much higher terbinaﬁne ion signals were
detected in the samples collected from those regions
(#1-9 in Fig. 3b). Most sebaceous glands are attached
to hair follicles, which with the arrector pili muscle
comprise the pilosebaceous unit. Figure 3c shows
the distribution of terbinaﬁne on skin throughout
the body, where higher levels of terbinaﬁne were
detected in the samples collected from sebaceousgland-rich areas (e.g. the face) than those from
gland-sparse areas (e.g. the limbs). The highest
terbinaﬁne ion signals were detected in the samples
collected from the forehead and chin (#1e9 in
Fig. 3), while the lowest terbinaﬁne ion signals were
detected in the samples collected from the lips. The
vermilion border of the lips is the only part of the
face where the oral mucosa is continually exposed to
the external environment. The skin of the lips has no

hair follicles, no sweat glands, and no sebaceous
glands. Therefore, very low terbinaﬁne ion signals
were detected on the lips, suggesting that the terbinaﬁne secreted onto the skin around the lips may
have been detected because the subject pursed his
lips. In addition to the face, the ears, neck, chest,
armpits, and back are also rich in sebaceous glands
and consequently have higher terbinaﬁne levels.
These ﬁndings were in agreement with previous
studies (skin patch sampling) which found that
ingested terbinaﬁne was mostly delivered to the
stratum corneum, nails, and hair through sebaceous
glands, and to a minor extent by direct diffusion
through the dermis to the epidermis [50,54e57]. In
these studies, the highest concentrations of terbinaﬁne were accumulated in sebum and found to be
15%, 20%, 25% in the stratum corneum after 7, 12,
and 14 days of oral doses (250 mg/day), respectively.
Conversely, terbinaﬁne concentrations were
comparably lower in the hair and nails, while the
highly hydrophobic terbinaﬁne was not found in
sweat [50]. Moreover, previous studies also indicated that relative lower terbinaﬁne ion signals were
detected in the peripheral nails after several days of
medication [50].
It has been reported that the terbinaﬁne persisted
in plasma and peripheral tissue samples for prolonged periods after administration of the last dose.
The present study was undertaken to characterize
terbinaﬁne during an 8-week washout phase
following the last dose. Figure 4 shows the terbinaﬁne ion signals in sebum samples collected from
different skin regions of the onychomycosis patient
during the last week of medication and each week
after stopping medication up to 8 weeks. The
numbers at the top indicate the skin regions where
samples were collected (as designated in Fig. 3a and
b). Even up to 2 weeks after stopping terbinaﬁne
medication, strong terbinaﬁne ion signals were still
detected in the sebum samples collected from the
face of the patient (Regions #1e10). The terbinaﬁne
ion signals seem ﬂuctuate through the washout
phase. The possible reasons for this phenomenon
include (1) sebum production ﬂuctuates in response
to changing hormone levels, the consumption of
dietary fat or carbohydrate, body temperature, etc.
Since the composition and amount of sebum can be
inﬂuenced, secretion of sebaceous terbinaﬁne may
also quite dynamic; (2) the deviations of probesweeping sampling on human skin cannot be
eliminated; (3) other environment factors, such as
room temperature and humidity, may cause
different skin conditions and affect the samples
collecting. Although the terbinaﬁne ion signals
ﬂuctuate through the washout phase, the results of
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Fig. 4. Triplicate TD-ESI/MS/MS analyses of sebum samples collected from different skin regions of the onychomycosis patient after 12 weeks of
terbinaﬁne medication and each week after stopping medication up to 8 weeks. Numbers on each MRM current (terbinaﬁne, m/z 292/141) indicate
where the sebum samples sampled skin regions as designated by Fig. 3a.
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this study are consistent with previous pharmacokinetic studies, which indicated that a single dose of
terbinaﬁne has a half-life of 30 h in blood, where the
half-life is extended with an increase in dosage; the
ﬁnal half-life of terbinaﬁne after reaching equilibrium is about 16.5 days [49]. Terbinaﬁne ion signals
started to decrease after the third week of stopping
medication, and decreased signiﬁcantly after the
ﬁfth week as terbinaﬁne ion signals were only
detected in the sebum samples collected from the
upper body. No terbinaﬁne ion signals (S/N<3)
were detected in the sebum samples after stopping
medication for 8 weeks.
A directly and rapidly AIMS approach for
detecting ingested drugs via human skin has alternatively been developed, drug distribution of body
locations on the skin was efﬁciently studied and the
drug ion signal in different time after medication
was accessibly monitored.

4. Conclusions
Skin and sebum proﬁles provide conveniently
accessible information about the underlying drug
metabolisms of the human body. In this study,
probe sampling combined with TD-ESI/MS/MS
analyses was used to rapidly detect the anti-fungal
agent terbinaﬁne in the sebum samples collected
from different skin regions. Since sampling was
easy and no sample preparation was required (e.g.
solvent extraction, concentration, or matrix application), each analysis was completed within 30 s.
Replicate analyses of terbinaﬁne yielded satisfactory
repeatability (RSD ¼ 16.38%) and sensitivity (0.1 ng/
mL). The terbinaﬁne ion signals detected at
different skin regions indicated that terbinaﬁne
levels were higher in the samples collected from
sebaceous-gland-rich areas, especially in facial regions like the forehead, nose, cheeks, and chin; low
terbinaﬁne ion signals were detected in sweatgland-rich areas such as the inner thighs, abdomen,
and back. The terbinaﬁne ion signal on patient's
skin was monitored for 8 weeks after medication
was terminated. Multi-drugs on skin can also be
characterized after drug-medication. The novelty
and signiﬁcance of this work are concluded as two

point: (1) directly and rapidly detecting ingested
drugs via human skin by Ambient ionization mass
spectrometry (AIMS). (2) using such a highthroughput approach, drug distribution of body
locations on the skin was efﬁciently studied and the
drug ion signal in different time after medication
was accessibly monitored. The results suggested the
potential for the use of TD-ESI/MS/MS to rapidly
characterize crucial drug for pharmacokinetic
studies.
Detection of the ingested terbinaﬁne on skin is
only a representative instance to demonstrate the
capability for applying ambient ionization mass
spectrometry in medical research. The developed
analytical platform has an additional potential to
help personalized medicine (precision medicine).
For example, previous study showed the ﬁnal
elimination half-life is changed in patients with
impaired liver or renal function, this will make the
clearance rate of terbinaﬁne be decreased. Monitoring of terbinaﬁne on skin can give more effective
medical decisions, practices, or interventions to the
individual patient. Since the changes in skin
metabolite proﬁles can grant insight into pathophysiological changes of studied individuals,
monitoring the ion signals of speciﬁc ingredient
secreted on skin instantly can give valuable information for optimal treatments or cures.
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Fig. S1. (a) TD-ESI full scan mode mass spectra for terbinaﬁne standards at concentrations of 0.1, 0.5, and 5 mg/mL (Inset: MS/MS analysis of
terbinaﬁne). (b) TIC of terbinaﬁne standards (MRM for m/z 292/141) at concentrations of 1, 10, and 100 ng/mL. (c) Calibration curve of terbinaﬁne
standards ranges from 1 to 100 ng/mL.

Fig. S2. TIC of terbinaﬁne (MRM for m/z 292/141) from ten consecutive analyses of a terbinaﬁne-applied region (ca. 2 cm  2 cm) on the back of the
hand of the unmedicated control. The sampled area was smeared with terbinaﬁne standard solution (2 mL, 100 ng/mL) and allowed to air-dry.
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